# A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.

> **NCT03169959** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 85 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** 2.5 mg Saxagliptin tablet
- **DRUG:** 5 mg dapagliflozin / 1000 mg metformin XR tablet
- **DRUG:** Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR
- **DRUG:** 5 mg saxagliptin
- **DRUG:** 10 mg dapagliflozin / 1000 mg metformin XR tablet
- **DRUG:** Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR

## Key facts

- **NCT ID:** NCT03169959
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-29
- **Primary completion:** 2017-08-03
- **Final completion:** 2017-08-03
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2017-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03169959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03169959, "A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03169959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*